Table 5.
Baseline previously recorded comorbidities in study participants.
| Overall | Discovery cohort | Validation cohort | |
|---|---|---|---|
| Use of lipid lowering drugs, N (%) | 391 (20.6%) | 312 (20.0%) | 79 (23.5%) |
| Hypertension, N (%) | 474 (25.0%) | 387 (24.8%) | 87 (25.9%) |
| Myocardial infarction, N (%) | 75 (4.0%) | 58 (3.7%) | 17 (5.1%) |
| Stroke, N (%) | 61 (3.2%) | 47 (3.0%) | 14 (4.2%) |
| Type 1 diabetes, N (%) | 4 (0.2%) | 3 (0.2%) | 1 (0.3%) |
| Type 2 diabetes, N (%) | 90 (4.7%) | 72 (4.6%) | 18 (5.4%) |
| Hypothyroidism, N (%) | 26 (1.4%) | 22 (1.4%) | 4 (1.2%) |
| Hyperthyroidism, N (%) | 9 (0.5%) | 8 (0.5%) | 1 (0.3%) |
| COPD, N (%) | 61 (3.2%) | 51 (3.3%) | 10 (3.0%) |
| Asthma, N (%) | 101 (5.3%) | 77 (4.9%) | 24 (7.1%) |
| Liver steatosis, N (%) | 204 (10.8%) | 195 (12.5%) | 9 (2.7%) |
| Liver cirrhosis, N (%) | 16 (0.8%) | 13 (0.8%) | 3 (0.9%) |
| Alzheimers, N (%) | 1 (0.05%) | 1 (0.06%) | 0 (0%) |
| Parkinsons, N (%) | 3 (0.2%) | 0 | 3 (0.9%) |
| Epilepsy, N (%) | 29 (1.5%) | 26 (1.7%) | 3 (0.9%) |
| Depression, N (%) | 311 (16.4%) | 265 (17.0%) | 46 (13.7%) |
| Anxiety disorder, N (%) | 68 (3.6%) | 64 (4.1%) | 4 (1.2%) |
| Osteoporosis, N (%) | 61 (3.2%) | 51 (3.3%) | 10 (3.0%) |
| Chronic renal failure according to Estimated Glomerular Filtration Rate (CDK-EPI) in ml/min/1,73 m2, N (%) | |||
| Stadium 1: eGFR ≥ 90 | 712 (37.6%) | 594 (38.1%) | 118 (35.1%) |
| Stadium 2: eGFR 60-89 | 987 (52.1%) | 812 (52.1%) | 175 (52.1%) |
| Stadium 3: eGFR 30-59 | 183 (9.7%) | 141 (9.0%) | 42 (12.5%) |
| Stadium 4: eGFR 16-29 | 4 (0.2%) | 3 (0.2%) | 1 (0.3%) |
| Stadium 5: eGFR ≤ 15 | 3 (0.2%) | 3 (0.2%) | 0 (0%) |
| eGFR Unknown | 6 (0.3%) | 6 (0.4%) | 0 (0%) |
| Risk scores | |||
| No. Framingham score available, N (%) | 1365 (72.0%) | 1131 (72.5%) | 234 (69.6%) |
| High Risk >20% | 321 (16.9%) | 266 (17.1%) | 55 (16.3%) |
| Intermediate risk 10%-20% | 485 (25.6%) | 391 (25.1%) | 94 (27.8%) |
| Low Risk <10% | 559 (28.2%) | 474 (30.4%) | 85 (36.3%) |
| Unable to calculate/unknown | 530 (28.0%) | 428 (27.5%) | 102 (30.4%) |
N, Number of Participants; IQR, Inter Quartile Range; COPD, Chronic Obstructive Pulmonary Disease.